



**INTERNAL DRAFT ONLY**

**NEWS RELEASE**

## **Canadian Biotech Company signs Cooperative Service Agreement with the USDA National Wildlife Research Center**

**Halifax, Nova Scotia, February 14, 2003** – ImmunoVaccine Technologies Inc. (IVT) announced today the completion of a Cooperative Service Agreement with the Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center (NWRC), a part of the United States Department of Agriculture located in Fort Collins, Colorado.

IVT is a vaccine enhancement company with a unique platform technology, *VacciMax*<sup>™</sup>, which can be applied to most human and veterinary vaccines and immunotherapies. The agreement pertains to IVT's first product derived from this platform, SpayVac<sup>™</sup>, a contraceptive vaccine for veterinary applications. Wildlife research physiologists at USDA NWRC have developed a new adjuvant that will likely be acceptable to the US FDA as a final product formulation. This new patent pending adjuvant is included in the SpayVac<sup>™</sup> wildlife formulation. NWRC is testing SpayVac<sup>™</sup> for contraception in white-tailed deer, and has agreed to expand these studies with SpayVac<sup>™</sup> to other wildlife species. SpayVac<sup>™</sup> is unique in that a single dose of the vaccine can provide 100% contraception for multi-year periods in several wildlife species.

The first field trial of SpayVac<sup>™</sup> for white-tailed deer began in Cleveland, OH, in January 2003. Other deer trials are being planned for Maryland, Georgia, New Jersey, and Texas, with projects involving other wildlife species being planned as well. IVT is coordinating these trials with its wildlife development partner, TerraMar Environmental Research Ltd., Sidney, British Columbia.

In addition, the agreement stipulates that IVT and NWRC will coordinate their efforts for regulatory approval of SpayVac<sup>™</sup> in the USA. NWRC addresses issues related to wildlife damage management through research and methods development, and maintains several field stations throughout the USA. It is the United States' federal government leader in finding effective, science-based solutions to wildlife damage management.

Dr. Warwick Kimmins, President and CEO of IVT, said "This agreement is a welcome validation of SpayVac<sup>™</sup> for a unique, humane product produced by a Nova Scotia company. I have been extremely impressed with the professionalism and level of science that the National Wildlife Research Center brings to this relationship."

ImmunoVaccine Technologies Inc. is involved in the development of new and more potent human vaccines as well. Other IVT projects include industry relationships to develop potential human vaccines for Hepatitis B, Pseudomonas and cancer. The *VacciMax*<sup>™</sup> vaccine enhancement technology used in SpayVac<sup>™</sup> was originally developed at Dalhousie University, Halifax, Nova Scotia.

*ImmunoVaccine Technologies Inc. is seeking other agreements for vaccine product development with industry partners.*

**For more information contact:**

**Dr. Warwick Kimmins, President & CEO**

Phn: 902-492-1819 Email: [ivt@immunovaccine.com](mailto:ivt@immunovaccine.com)